Clinical Trial Search

Primary: Response Rate [Complete Response (CR) and Partial Response (PR)] — 0; 0; 0; 1 participants

Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients

Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants

Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…

Primary: Complete Response or Partial Response Based on M-Protein Assessments Only — 0; 0 Participants

Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)

Primary: Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1). — 56; 30 mg/m^2

Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…

Primary: Best Overall Response Rate (ORR) — 16.7; 23.7 % of participants w/ PR or better

Primary: Number of Patients Exhibiting a Given Overall Response as Determined by Investigator — 0; 0; 0; 0 participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxcity (DLT) — 0; 0; 1; 1 Participants

Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants

Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…

Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide — 64 percentage of participants

Primary: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) — 2.6; 1.7 months — p==0.0054

Primary: Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory…

Primary: Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE)…

Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants

Primary: Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer. — 0 participant response

Primary: Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087 — 16; 16; 16; 16 mg/kg

Primary: Proportion of Confirmed Responses With Ixazomib Citrate Alone (Arm A [Closed]), Ixazomib Citrate With Dexamethasone (Arms B + C), or With Dexamethasone and…

Primary: Overall Response Rate — 6; 1; 20; 43 Participants

Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants

Primary: Best Overall Response Rate (ORR) in the Response Evaluable Subset Population — 16.1; 39.6; 53.0 percentage of participants

Primary: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants — 27; 24 percentage of participants — p=0.4859

Primary: MTD, Defined as the Highest Dose in Which =< 1/6 Patients Experience a Dose-limiting Toxicity, Graded According to the National Cancer Institute Common Terminology…

Primary: Response Rate, Defined as the Number of Patients Achieving Complete Response (CR), Partial Response (PR), or Minor Response (MR) — 5; 2; 3; 1 Participants

Primary: Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria — 0; 7.6; 7.6; 15.4 percentage of…

Primary: Overall Survival — 10.0; 10.2 months — p=0.4172